Drug Profile
Research programme: synthetic macrocycles - Ensemble Therapeutics
Alternative Names: E-36041; IDO checkpoint inhibitors; ubiquitin proteasome inhibitorsLatest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Ensemble Discovery
- Developer Ensemble Therapeutics; Novartis
- Class Antineoplastics; Macrocyclic compounds; Small molecules
- Mechanism of Action Checkpoint kinase inhibitors; Cyclophilin D inhibitors; Cyclophilin inhibitors; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Inhibitor of apoptosis protein inhibitors; Interleukin 17 receptor antagonists; PCSK9 protein inhibitors; Tryptophan oxygenase inhibitors; Ubiquitin thiolesterase modulators; USP28 protein inhibitors; Usp30 protein inhibitors; USP9X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Cancer; Cardiovascular disorders; Diabetes mellitus; Hepatitis B; Inflammation; Pain; Parkinson's disease; Reperfusion injury; Rheumatoid arthritis
Most Recent Events
- 24 Feb 2023 Discontinued - Preclinical for Cancer in USA (PO)
- 24 Feb 2023 Discontinued - Preclinical for Inflammation in USA (PO) (Novartis pipeline, February 2023)
- 24 Feb 2023 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO) (Novartis pipeline, February 2023)